Study Groups of Project 9: Chronic myeloproliferative diseases (CMPD)
|
Name of the study group |
European LeukemiaNet Eosinophilia Study Group |
|---|---|
|
Disease(s) |
Eosinophilia associated chronic myeloproliferative disorders (e. g. idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, atypical chronic myeloid leukemia with eosinophilia, systemic mastocytosis with eosinophilia) |
|
Leader(s) of the study group |
Prof. J. Apperley Imperial College School of Medicine Hammersmith Hospital London, UK j.apperley@ic.ac.uk Prof. G. Martinelli Institute of Hematology and Medical Oncology "L. and A. Seràgnoli. University of Bologna, Via Massarenti, 9-40138 Bologna, Italy. gmartino@kaiser.alma.unibo.it Dr. A. Reiter III. Medizinische Universitätsklinik, Klinikum Mannheim der Universität Heidelberg, Wiesbadener Str. 7-11, 68305 Mannheim. Germany andreas.reiter@med3.ma.uni-heidelberg.de Prof. N. C. P. Cross Wessex Regional Genetics Laboratories, Salisbury, U.K. & Human Genetics Research Division, University of Southampton School of Medicine, Southampton, UK ncpc@soton.ac.uk Prof. Saglio Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, 10043 Orbassano-Turin, Italy. giuseppe.saglio@unito.it Dr. J. Cools Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium jan.cools@med.kuleuven.ac.be Dr. D. Cilloni Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, 10043 Orbassano-Turin, Italy. daniela.cilloni@unito.it Prof. C. Preudhomme Laboratoire d'Hématologie A, Hôpital Calmette-CHU of Lille, France; Unité INSERM-U524-Lille cpreudhomme@chru-lille.fr Dr. A. Sureda Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, St Antoni Maria Claret, 167, 08025 Barcelona, Spain. asureda@hsp.santpau.es |
|
Website |
http://www.leukemia-net.org/ |
|
Studies |
Italy Imatinib in HES (Principal investigator: Prof. G. Martinelli, Bologna, see above) Germany Evaluation of the efficacy, safety and tolerability of imatinib mesylate (Glivec ) in patients with idiopathic hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL) and systemic mastocytosis with eosinophilia (SME). (Phase II). (Principal investigator: PD Dr. A. Reiter, Mannheim, see above) UK Contact person: Prof. J. Apperley, London, see above (for shortprotocols, see studies) |
|
Contact persons |
See above |
|
Diagnostic Labs |
Prof. Dr. N.C.P. Cross Wessex Regional Cytogenetics Centre, Salisbury, United Kingdom. ncpc@soton.ac.uk PD Dr. A. Reiter III. Medizinische Universitätsklinik, Klinikum Mannheim der Universität Heidelberg, Wiesbadener Str. 7-11, 68305 Mannheim, Germany andreas.reiter@med3.ma.uni-heidelberg.de Prof. Dr. Saglio Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, 10043 Turin, Italy. saglio@csi.it Dr. J. Cools Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium jan.cools@med.kuleuven.ac.be Prof. Dr. C. Preudhomme Laboratoire d'Hématologie A, Hôpital Calmette-CHU of Lille, France; Unité INSERM-U524-Lille cpreudhomme@chru-lille.fr |